QbD Group
    Validating Single-Use Systems in Biopharma: Key Requirements and Emerging Expectations

    Validating Single-Use Systems in Biopharma: Key Requirements and Emerging Expectations

    Learn the key requirements for validating Single-Use Systems, with guidance on supplier control, compliance, and Extractables & Leachables risk management.

    Single-Use Systems (SUS) have become a fundamental component of modern biopharmaceutical manufacturing. Their flexibility, reduced cleaning requirements, and rapid deployment make them ideal for dynamic processes such as cell culture, buffer preparation, purification steps, and fill–finish operations.

    However, as SUS rely on polymer-based materials, Quality and Validation teams must not only ensure robust functional validation but also consider the potential chemical risks associated with Extractables & Leachables (E&L).

    Regulators increasingly expect manufacturers to demonstrate control over both dimensions — operational performance and material compatibility — making the validation of SUS a multidimensional task where quality, compliance, and E&L risk management converge.

    1. Supplier Qualification and Material Traceability

    The foundation of SUS validation begins with supplier qualification. Since SUS are manufactured using complex supply chains, Quality teams must ensure that vendors provide:

    • Complete material specifications
    • Certificate of compliance for process-contact components
    • Change control mechanisms
    • Robust quality systems and audit readiness

    Traceability is critical. Regulators expect manufacturers to demonstrate full visibility into the materials that come into contact with process fluids. When components are preassembled, pre-sterilized, or sourced from multiple suppliers, the validation burden increases significantly.

    2. Ensuring Fitness for Intended Use

    Validating SUS is not just about confirming functionality — it is about proving that each component is suitable for its specific process application. This includes evaluating:

    • Mechanical integrity (pressure, torque, sealing, tensile strength)
    • Sterility assurance and sterilization compatibility
    • Integrity testing before and after use
    • Compatibility with process fluids, operating conditions, and mixing parameters

    Regulators expect documented evidence that the SUS configuration used in manufacturing aligns with the conditions assessed during validation. Any deviation (e.g., different tubing type, new filter model, alternate connector) can require requalification or additional justification.

    3. Quality Documentation and Inspection Readiness

    A complete validation package must include clear, traceable documentation that supports decision-making. This typically involves:

    • Design qualification (DQ) based on process requirements
    • Installation qualification (IQ) including component identification
    • Operational qualification (OQ) demonstrating functional performance
    • Standard operating procedures for assembly, handling, and disposal
    • Risk assessments aligned with ICH Q9(R1) principles

    Auditors routinely request evidence that SUS have been evaluated systematically, that change controls are in place, and that Quality has visibility over supplier reliability and component consistency.

    4. Where Extractables & Leachables (E&L) Strengthen the Validation Framework

    While mechanical and functional validation ensure the system works as intended, they do not address the chemical risks associated with polymer-based materials. This is where Extractables & Leachables (E&L) assessments become a crucial complement to the overall validation strategy.

    SUS materials can release chemical compounds under certain temperature, pH, and process conditions. Regulators increasingly expect manufacturers to demonstrate that these compounds:

    • Are identified and assessed
    • Pose no risk to product quality or patient safety
    • Are evaluated using justified, traceable toxicological frameworks
    • Are supported by appropriate supplier or custom studies

    However, interpreting extractables datasets — often hundreds of pages — requires specialized expertise in both analytical chemistry and toxicology.

    Conclusion

    Single-Use Systems bring tremendous advantages to biopharmaceutical manufacturing, but they also introduce new validation and compliance responsibilities. By building a robust validation framework — and complementing it with accurate E&L assessment when needed — Quality teams can confidently demonstrate control, maintain inspection readiness, and protect product integrity.

    About the Author

    Jo Doucet
    Jo Doucet

    Global Head Qualification & Validation

    Jo Doucet is an expert in qualification and validation with over 20 years of experience in the pharmaceutical industry. He leads the Qualification/Validation division at QbD Group, supporting teams and clients in GxP compliance projects across manufacturing, IT, QC, and medical devices.

    QbD Group

    Ready to accelerate your life sciences project? Talk to our experts.

    Get expert guidance →
    Share this article

    Subscribe to the latest updates in life science

    Expert perspectives delivered to your inbox — pick your interests.

    No spam, ever. Unsubscribe anytime.

    Keep reading

    Related articles

    We use cookies to enhance your experience

    We use essential cookies for site functionality and optional analytics cookies to improve our services. Read our Privacy Policy and Cookie Policy.